Literature DB >> 15242531

Immune responses to recombinant adeno-associated virus vectors: putting preclinical findings into perspective.

Terence R Flotte1.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15242531     DOI： 10.1089/1043034041361190

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  5 in total

1.  NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS.

Authors:  Venu Talla; Hong Yu; Tsung-Han Chou; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; Alfred S Lewin; John Guy
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

Review 2.  Molecular Therapies for Muscular Dystrophies.

Authors:  Ava Y Lin; Leo H Wang
Journal:  Curr Treat Options Neurol       Date:  2018-06-21       Impact factor: 3.598

3.  Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airway.

Authors:  Stephanie G Sumner-Jones; Deborah R Gill; Stephen C Hyde
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

4.  Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.

Authors:  Zhaobing Ding; Cary O Harding; Alexandre Rebuffat; Lina Elzaouk; Jon A Wolff; Beat Thöny
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

5.  Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats.

Authors:  Benjamin Storek; Nina M Harder; Michaela S Banck; Cheng Wang; Douglas M McCarty; William Gm Janssen; John H Morrison; Christopher E Walsh; Andreas S Beutler
Journal:  Mol Pain       Date:  2006-01-30       Impact factor: 3.395
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.